M4MM

Compass Pathways Advances Psilocybin Research in the UK

LOS ANGELES- Compass Pathways, a biotechnology company specializing in mental health innovations, has commenced the UK segment of its global Phase 3 clinical trial evaluating COMP360 psilocybin therapy for treatment-resistant depression (TRD). This initiative follows ...

Monday: Cannabis Capital Markets: Roundup

NEW YORK- Many cannabis investors are waiting for legalization in the United States to act as a catalyst. The stock market is volatile as progress toward that aim ebbs and flows, and investors keep an ...

  • Seizure of Contraband

Open Book Extracts Raises Series C Funding Round

ROXBORO, N.C. -- Open Book Extracts (OBX), providing high quality cannabinoid ingredients, concept-to-market formulation services, and finished goods manufacturing for the industry's leading brands, announced the first close of a Series C equity financing round. This ...

Subscribe To Our Newsletter